What are the growth charts for genotropin use?

Why do doctors use growth charts with Genotropin?

Doctors track height, weight, and growth velocity on standard pediatric charts during Genotropin therapy. These charts help measure how a child responds to treatment and decide whether to adjust the dose. The charts themselves are not drug-specific; they are CDC or WHO reference curves that show typical ranges for age and sex.

What growth parameters do doctors actually monitor?

The main values plotted are height-for-age, weight-for-age, and height velocity. Height velocity, the centimeters grown per year, is the clearest indicator of response. Doctors usually compare a child's measurements against sex-specific 3rd, 50th, and 97th percentiles on the charts.

Can Genotropin treatment push a child beyond normal ranges?

Some children overshoot the normal range and exceed the 97th percentile if they receive long doses or receive treatment in late adolescence. Physicians adjust doses to target a height within the normal range rather than aiming for unusually tall stature.

When does treatment usually end?

Treatment stops when bone age reaches 14 years for girls or 16 years for boys, or when near-adult height is reached. Growth charts show the final height outcome after therapy ends.

What happens if growth velocity falls short of expectations?

If a child does not show adequate height gains on the charts, doctors may raise the dose, check for other medical conditions, or stop treatment if the response remains poor. Growth-chart data help clinicians decide these steps.

How do patents affect availability of Genotropin alternatives?

Pfizer holds composition-of-matter and method-of-use patents on Genotropin that protect the recombinant growth hormone formulation. These patents are listed on DrugPatentWatch.com. [1]